The Prescription For Better Access Podcast

Sarah Emond’s prescription for better access? Prices set in line with value, met by streamlined access with little to no cost sharing or utilization management. Hear the whole episode here: youtube.com/watch?v=DaFbdSgC… #PrescriptionForBetterAccess

“We can become the healthiest nation, not the sickest one.” In our latest episode, Emily Gibb of @Novartis and Casey Cormier of Stratis Group share their prescriptions for better access. Watch📺here: [lnkd.in/eBF86giR] Listen🎧 here: [lnkd.in/eBF86giR]

New episode 🎙️ Scott Howell & Mark Hansan talk with Jonathan Blum on the future of U.S. drug policy—IRA trade-offs, 2026 Part D redesign, M3P, and balancing affordability & innovation. Must-listen for #access #coverage #drugpricing. 🎧 lnkd.in/eaCurzQb

New episode – live from ACCESS US 2025! Can we improve drug affordability without stalling innovation? Scott Howell & Mark Hansan lead a powerful convo w/ leaders from BMS, ICER, NPC & Accenture on pricing, PBMs, AI & what’s next for patient access. shorturl.at/FEd3O

Episode 29 of the podcast is now live! We called this episode The Domino Effect because so many of the challenges with #drugaccess and #affordability can be traced back to one foundational issue: benefit design. Listen now: prescriptionforbetteraccess.…

We've got an exciting new episode coming your way next week--while you wait, don't miss our April episode with Brian Reid, MS, editor at Cost Curve. Listen here: prescriptionforbetteraccess.…

Don't forget! This month we released an episode with #BrainReid of #CostCurve digging into his approach towards #healthcare and #drugpricing reporting. Listen here: prescriptionforbetteraccess.…

NEW EPISODE: #DrugPricing is of the most debated — and misunderstood — issues in #healthcare. In our latest episode, we talk with Brian Reid, MS, Principal at Reid Strategic and editor of #CostCurve, one of the smartest voices cutting through the noise. bit.ly/3EsnACQ

New episode! Mark and Scott chat with Sarah Emond of ICER on patient access and the forecast for 2025! bit.ly/41aayBh

New episode! Mark and Scott chat with Sarah Emond of ICER on patient access and the forecast for 2025! bit.ly/41aayBh

New episode! Check out Mark and Scott's conversation about patient access with Sarah Emond, MPP, President and CEO of ICER. bit.ly/41aayBh #patientaccess

NEW EPISODE ALERT Sarah Emond, MPP, President & CEO of the Institute for Clinical and Economic Review (ICER), joins me and Scott Howell for a timely discussion on the challenges and opportunities in drug pricing and patient access. bit.ly/41aayBh

New podcast episode! Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center discusses the critical healthcare and policy trends shaping 2025. bit.ly/3BxHniT

Check out our latest conversation with Stacie Dusetzina, PhD from Vanderbilt University about critical healthcare and policy trends shaping 2025! #healthcare #patientaccess bit.ly/3BxHniT

Catch our latest episode with Stacie Dusetzina, PhD from Vanderbilt University where we discuss #drugpricing and more! bit.ly/3BxHniT

Mark and Scott interview Stacie Dusetzina, Ph.D., of Vanderbilt University about the state of drug pricing and more for 2025. Tune in here to listen: bit.ly/3BxHniT #patientaccess #drugpricing

Check out the new episode! Mark and Scott talk to Stacie Dusetzina of #VanderbiltHealth about her outlook for 2025. Listen to the episode here: bit.ly/3BxHniT

New episode! Mark Hansan and Scott Howell wrap up 2024 with Stacie Dusetzina, PhD, Professor at #VanderbiltUniversity and researcher and expert in pharmaceutical and health policy. Stacie helps us better understand the policy outlook for 2025 and beyond. bit.ly/3BxHniT